每经AI快讯,10月14日,据葛兰素史克消息,中国国家药监局已批准欣安立适(葛兰素史克重组带状疱疹疫苗(CHO细胞))用于18岁及以上因已知疾病或治疗(如自体造血干细胞移植)造成免疫缺陷或免疫抑制从而导致带状疱疹发病风险增加的成人预防带状疱疹。(文章来源:每日经济新闻)
Source Link每经AI快讯,10月14日,据葛兰素史克消息,中国国家药监局已批准欣安立适(葛兰素史克重组带状疱疹疫苗(CHO细胞))用于18岁及以上因已知疾病或治疗(如自体造血干细胞移植)造成免疫缺陷或免疫抑制从而导致带状疱疹发病风险增加的成人预防带状疱疹。(文章来源:每日经济新闻)
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.